Inhibition of lactate transport by MCT-1 blockade improves chimeric antigen receptor T-cell therapy against B-cell malignancies

BACKGROUND: Chimeric antigen receptor (CAR) T cells have shown remarkable results against B-cell malignancies, but only a minority of patients have long-term remission. The metabolic requirements of both tumor cells and activated T cells result in production of lactate. The export of lactate is faci...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez, Ernesto, Karattil, Rajesh, Nannini, Francesco, Weng-Kit Cheung, Gordon, Denzler, Lilian, Galvez-Cancino, Felipe, Quezada, Sergio, Pule, Martin A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314680/
https://www.ncbi.nlm.nih.gov/pubmed/37399358
http://dx.doi.org/10.1136/jitc-2022-006287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314680/
https://www.ncbi.nlm.nih.gov/pubmed/37399358
http://dx.doi.org/10.1136/jitc-2022-006287

Ejemplares similares